Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jul-Aug;45(4):334-8.
doi: 10.4103/0253-7613.115000.

A comparative study of efficacy and safety of gabapentin versus amitriptyline as coanalgesics in patients receiving opioid analgesics for neuropathic pain in malignancy

Manasi Banerjee  1 , Santanu Pal, Biswamit Bhattacharya, Balaram Ghosh, Shirsendu Mondal, Joydeep Basu
Affiliations
Randomized Controlled Trial

A comparative study of efficacy and safety of gabapentin versus amitriptyline as coanalgesics in patients receiving opioid analgesics for neuropathic pain in malignancy

Manasi Banerjee et al. Indian J Pharmacol. 2013 Jul-Aug.

Abstract

Objective: To assess the efficacy and safety of gabapentin and amitriptyline along with opioids in patients suffering from neuropathic pain in malignancy.

Materials and methods: Eighty-eight adult patients between 18 and 70 years of age with neuropathic pain in stage III malignant disease, matched for baseline charactistics, were randomly assigned to two groups. Group A received oral tramadol and gabapentin and group B received oral tramadol and amitriptyline. The treatment duration of each patient was 6 months. Visual analog scale (VAS) was the primary efficacy parameter. Verbal rating scale (VRS) score, percentage of pain relief (PPR), and global pain score (GPS) were the secondary efficacy parameters. Oral morphine tablets or fentanyl transdermal patch were used as rescue medication. Data analysis was carried out in Graph Pad instat.

Results: There was decline in VAS pain score from baseline in both the groups in the early phase of the study though there was no statistically detectable difference between them at any study point. Similar changes were seen in the secondary efficacy parameters too. Thus both the drugs were effective in providing relief to cancer patients with neuropathic pain though there was no statistically detectable difference in efficacy between them. Six patients in group A and eight patients in group B required rescue medication. A total of 12 subjects in the gabapentin group and 15 subjects in the amitriptyline group experienced adverse events which were of mild to moderate grades.

Conclusions: Amitriptyline may be a suitable alternative for management of neuropathic pain in cancer patients although gabapentin is widely used for this purpose. The lower cost of amitriptyline may favor patient compliance with lesser number of drop-outs.

Keywords: Amitriptyline; coanalgesics; gabapentin; neuropathic pain.

PubMed Disclaimer

Conflict of interest statement

Conflict Interest: None declared

Figures

Figure 1
Figure 1
Changes in VRS score between the two groups. [P> 0.05]
Figure 2
Figure 2
Changes in PPR score between the two groups. [P > 0.05]
Figure 3
Figure 3
Changes in GPS score between the two groups. [P> 0.05]
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Emanuel EJ, Hauser J, Emanuel LL. Palliative and end of life care. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., editors. Harrison's Principles of Internal Medicine. 17th ed. New York: McGraw Hill; 2008. pp. 70–1.
    1. Serpell MG. Gabapentin in neuropathic pain syndromes: A randomized double-blind placebo-controlled trial. Pain. 2002;99:557–66. - PubMed
    1. Bennett M, Simpson KH. Gabapentin in treatment of neuropathic pain. Palliat Med. 2004;18:5–11. - PubMed
    1. Kalso E, Tasmuth T, Neuvonen PJ. Amitrytiline effectively relieves neuropathic pain following treatment of breast cancer. Pain. 1996;64:293–302. - PubMed
    1. Caraceni A, Zecca E, Martini C, Bonezzi C, Arcuri E, De Conno F, et al. Gabapentin for Neuropathic Cancer Pain: A Randomized controlled trial from the gabapentin cancer pain study group. J Clin Oncol. 2004;22:2909–17. - PubMed

Publication types

MeSH terms